Tuesday, May 15, 2012

Laser Therapy in an Injury Rehabilitation Clinic


Tuesday, May 29, 2012 1:00 PM - 2:00 PM EDT

Webinar Registration

Below are a few items that will be covered in the Webinar:
Learn how laser can be used by a multidisiplinary rehab team of health providers.
Review common treatments and laser protocols for chronic and acute injuries.
Gain valuable tips on billing for laser through 3rd party payers.
* 
* 
*  
* 
* 
* 
* 
* 
* 
* 

Webinar organizers are prohibited from soliciting confidential personal information (credit card information, social security numbers, etc.) in the registration form. This questionnaire is not intended to handle sensitive data.
* 
* Indicates a required field
By clicking the "Register Now" button you submit your information to the Webinar organizer, who will use it to communicate with you regarding this event and their other services.

Monday, May 14, 2012

Natural Alternatives for Mosquito Management


From The American Chiropractic Association (ACA)

The summer months are upon us—sunshine, Bar-B-Qs, and …mosquitoes! With reports of mosquito-carried diseases such as West Nile Virus, which killed 124 people in 2007,1 many consumers turn to bug repellants available on the market. Some sprays, however, carry insecticides such as DEET, Permethrin and Picaridin, and may do more harm than good to human health.
According to the Department of Health and Human Services and the Pesticide Information Profile Extension Toxicology Network, DEET has the potential to cause rashes, breathing difficulties, neurotoxic effects, and even death, especially in susceptible individuals and those overusing the chemical. Studies have also shown that the chemical is transported from the skin to all organs of the body, enters the brain, can be transferred to babies via breast milk, and can even reach the fetus.2, 3
What other options are available?
With studies and stories documenting the negative effects of DEET and other insecticides, consider other options for deterring mosquitoes and other pests. According to the Centers for Disease Control and Prevention, bug repellants using oil of lemon eucalyptus as their main ingredient, such as Repel Lemon Eucapyptus insect repellant, were found to provide similar protection to those using low concentrations of DEET.4
Several other options also use a more natural and traditional approach to repelling mosquitoes and other pests such as ticks and flies:
Product
Instructions
Bite BlockerTM
Using soybean oil, coconut oil, and geranium oil, this product has been shown to keep bugs away for an average of 95 minutes. Several options, including formulas for kids and pets, are available in retail stores and online at www.homs.com.5
Burts Bees Herbal Insect RepellantTM
Eucalyptus and lemongrass repel mosquitoes in this oil that is rubbed onto the skin.
Essential oils: lemon eucalyptus, cedar wood, lemongrass, rosemary, clove, frankincense and peppermint
Dilute 10 drops of essential oil to 2 tablespoons of carrier oil (such as grape seed or vegetable oil) to prevent skin irritation that may occur from using the concentrated oil directly on your skin.
Neem oil:
Neem Aura Naturals Bug Disenchanter, Neem Tree Farms Botanical Outdoor Gel or Spray
Long seen as a solution to many health problems, Neem oil can also keep bugs at bay. Current research classifies Neem oil as relatively non-toxic, with even high amounts not causing problems. Caution is recommended for women of child bearing age and families trying to conceive.6
Catnip oil: Nature’s Herbal Mosquito & Insect Shield
Catnip oil has been shown by the American Chemical Society and USDA to be nearly as effective as DEET in repelling bugs without the harmful side effects.7
What else can I do?
To manage mosquitoes and other pests in your yard, take the following precautions:
  • Plant insect-repelling plants in your garden. Marigolds, geraniums, catnip, citronella grass, and mosquito plants naturally keep bugs away and look beautiful in your garden. Peppermint, lemon balm (citronella), rosemary, thyme, and other herbs also have mosquito-repelling properties. You can also crush the leaves of these plants to release the oils and put them in alcohol to make an insect-repelling spray.
  • Burn sandalwood sticks in your yard.
  • Eliminate standing water from your yard and neighborhood—this is where mosquito eggs flourish and eventually hatch.
  • Don’t wear lotions and perfumes while outdoors—the scents often attract mosquitoes and flies.
  • Burn citronella candles in outside areas with low wind.
  • Keep screens in doors and windows in good condition and sealed around the perimeter so mosquitoes and flies cannot enter the house.

Friday, May 11, 2012

O'Brien Winner Doesn't "Knee"d Surgery



While most champion four-year-olds are either occupied in the breeding shed or prepping for the upcoming stakes season, Up The Credit is earning a little extra credit doing double duty this spring.
Following a million-dollar sophomore campaign which included a victory in the $1.5 million North America Cup and divisional honours at the O’Brien Awards, trainer Carl Jamieson and his partners Thomas Kyron, Joanne Morrison, and Brian Paquet decided the son of Western Terror out of the Pacific Rocket mare Cantbuymehappiness would become a sire and continue to race as a four-year-old.
With Jamieson heading south to Florida for winter training, Up The Credit was placed with conditioner Mark Horner while he stands stud at Seelster Farms.
“Mark’s doing me a great deed by training him this winter and breeding him for me because he’s only 15 minutes away from Seelster Farms,” noted Jamieson, who will be returning home at the end of April.
“I picked him up December 29 to be exact,” said Horner from his St. Mary's, Ont. farm last week. “He jogged light until the first of February and then he started training. He’s been training now in 2:15 and that’s at home in the jog cart.”
Horner says Up The Credit gets his training sessions in between his Monday-Wednesday-Friday breeding schedule.
“He’s been a busy boy,” said Horner. “I don’t have the exact numbers as to how many mares he’s bred, but I know he’s been busy. Hopefully it stays that way.”
Near the end of his sophomore year, Up The Credit looked to be facing surgery on a knee that was injured as a freshman and had resulted in some calcification around the area once it healed. However, Jamieson says the issue has cleared up with some TLC and the procedure is no longer needed for him to continue racing.
“He’s 100 per cent,” confirmed Jamieson, who was nominated on the ballot for this year’s Canadian Horse Racing Hall of Fame inductions. “We thought last Fall we might have to do surgery on the knee, but we were using the laser on him all summer and fall and it healed the knee up and everything’s the same as he was born with. He never had surgery and he’s 100 per cent ready to go.”
“He seems to be in good shape and I’m really happy with his conditioning right now,” added Horner. “I think he’s good to go.”
Up The Credit is expected to qualify mid-April in preparation for the Molson Pace eliminations on May 18 at Western Fair Raceway. He has also been nominated to a handful of other open stakes including the Ben Franklin, Des Smith, Canadian Pacing Derby, U.S. Pacing Championship, and Breeders Crown.
“Obviously it’s tough and there’s a lot of nice horses out there,” said Horner of the step up in competition Up The Credit will face. “Anytime a four-year-old goes into the older pacing ranks it's tough so hopefully we’ve picked the right spots and he’s in great shape and he has lots of luck. I hope that he’s ultra competitive and I really can’t see why he wouldn’t be if he brings it up to the next level.”
Meanwhile, Up The Credit’s younger stablemate and fellow O’Brien Award winner Warrawee Needy is on track to follow in his footsteps down the road to North America Cup 29. More on him in the coming weeks as Trot Insider.


Up The Credit uses Theralase's Cold Laser Therapy for its knee issues. For more information please call 1-866-843-5273 or visit www.theralase.com.

Wednesday, May 9, 2012

Fewer Canadians are dying from cancer


While cancer remains the country’s biggest killer, the mortality rate – essentially an average Canadian’s risk of dying of cancer – has fallen markedly over the past generation.
The cancer death rate dropped 21 per cent in men and nine per cent in women between 1988 and 2007, according to new data from the Canadian Cancer Society.

The decrease is due principally to fewer Canadians smoking, along with more early detection and improved treatments.
“Without these changes, if smoking rates had remained the same, for example, we would have seen 100,000 more cancer deaths over the past 20 years,” Gillian Bromfield, director, cancer control policy at the CCS, said in an interview.
Slightly more men than women die of cancer: 52 per cent versus 48 per cent.
The gender gap, however, is closing, due largely to smoking patterns. Historically, far more men than women have smoked, but the decline in smoking has been more rapid in men than in women. Young women are also more likely to become new smokers.
An estimated 186,400 new cases of cancer will be diagnosed in Canada this year (a figure that does not include 81,300 cases of non-melanoma skin cancer), according to the CCS projections. More than two-thirds of people diagnosed with cancer survive five years or more.
It is estimated that there will be 75,700 cancer deaths in 2012.
Lung cancer is, by far, the biggest cancer killer, with 20,100 deaths, followed by colorectal cancer, 9,200, breast cancer 5,200, pancreatic cancer, 4,300, and prostate cancer, 4,000.
While those numbers are significant, the report shows that the mortality rate dropped for all major cancers over the past two decades, including:
* Lung cancer down 34 per cent in women, 30 per cent in men;
* Prostate cancer, 34 per cent decrease;
* Breast cancer, 32 per cent reduction;
* Colorectal cancer deaths down 24 per cent in men, 16 per cent in women;
* Pancreatic cancer, 14 per cent decline in men, two per cent in women.
Despite these improvements, the overall number of cancer cases diagnosed and number of cancer deaths are rising steadily due to population growth and aging. Cancer is principally a disease of aging, although individual risk depends on a combination of genetics, environmental factors and triggers.
Two-thirds of cancer deaths occur in people over the age of 50.
While there has been significant progress, more can still be done, Ms. Bromfield said, noting that about half of all cancer deaths are preventable, principally through lifestyle changes like smoking cessation.
“I grew up thinking that smoking was pretty cool,” said Marcie McCurlie, who started at age 16. She kept at it for a decade before quitting her pack-a-day habit for good earlier this year.
“I started to realize that smoking was aging me. It gives you wrinkles. I had asthma and I was getting sick all the time,” Ms. McCurlie said. “My doctor was a big influence in getting me to quit, and I feel a lot healthier now.”
David Hammond, an associate professor of public health at the University of Waterloo in Waterloo, Ont., said there have been significant declines in smoking rates – to 17 per cent today from 50 per cent – and it is reflected in the mortality statistics.
“But there are still 4.7 million Canadians who smoke, so we’ve got a long way to go.”
Dr. Hammond said the key is prevention – ensuring young people don’t start smoking in the first place.
He said many initiatives have been taken, such as outlawing smoking in workplaces and bars, and graphic illustrations on cigarette packages, but government could – and should go further – by mandating plain packaging and outlawing flavoured tobacco that appeals to young people.
Dr. Hammond said there is a need for far more support for people who are trying to quit smoking and a crackdown on contraband tobacco, because high prices are one of the best disincentives to new smokers.
The full report is available at: cancer.ca/Canada-wide.aspx?sc_lang=en

Modern pharmaceuticals becoming part of the culture in the NHL


Globe and Mail

You’re the average NHL player, which means you stand a shade over six feet tall, you weigh just over 204 pounds, and you’re about 27 years old.
Between October and April of any given year, you will drop your battered self into an airplane seat on 80 or so occasions and rack up between 50,000 and 90,000 air miles.
You play an average of three games a week, and most of the time you’re suffering from a sprain, a strain, a tear or a break of one type or another.
So what do you do to withstand the maelstrom? In many cases the answer lies in the miracle of modern pharmaceuticals.
“You’ve just played a game, you have to travel, you’re up early the next day for a practice, maybe you’ve slept badly, maybe you’ve got other things going on at home or wherever, so for sure, pills can become a popular option for some guys,” the Vancouver Canucks’ Alex Burrows, whose team has one of the most demanding travel schedules in the NHL, said earlier this season.
In speaking to more than a dozen current NHL players and to several agents and hockey executives over the past five months, it is apparent the nexus of scheduling, player safety and travel is forming a little-noticed backdrop to the coming collective bargaining between the league and its players.
The life of the modern NHL player is not all first-class charters and swank hotels, there is also an eye-glazing amount of drudgery and crippling late-night flights and early morning practices, all of it seasoned with a generous pinch of fear – of injury, of unemployment, of failing on the ice.
As grinds go it’s fun, and handsomely remunerated; players happily embark, but even the fittest risk becoming tenderized by the end.
One Western Conference star described the perilous cycle thusly: industrial quantities of caffeine or over-the-counter decongestants (or both) to get up for games, alcohol and/or sleeping pills to tamp down post-game adrenalin, get up early for video and practice, rinse, repeat.
Since the death of former New York Rangers enforcer Derek Boogaard, who accidentally overdosed on a cocktail of pain medication and booze last year, and the subsequent deaths of NHL tough guys Rick Rypien and Wade Belak, the league and its teams have followed up on a public pledge by commissioner Gary Bettman to amend the NHL’s substance-abuse and behavioural policy, and have quietly tightened the rules concerning the way medication is dispensed in dressing rooms.
Sources also said the two physicians who oversee the NHL/NHLPA substance-abuse and behavioural-health program, Brian Shaw and David Lewis, made a point during their annual tour of the league’s dressing rooms of stressing the perils of sharing pills, whether they are for pain or sleep. According to multiple sources, the NHL Players’ Association and the NHL had discussions before this past season to find ways to control the availability of drugs – some teams apparently now keep a detailed log of their players’ prescriptions and refills.
“They’re trying to do it in order to make steps in the right direction so that what happened [last] summer doesn’t happen again in the near future,” the Boston Bruins’ Milan Lucic said in an interview in the early stages of the season.
But as with most other aspects of the league, policies vary from team to team, and no system is perfect.
Conversations with players and other officials throughout the league reveal that while the prevalence of opiates such as Oxycodone in NHL dressing rooms has been well-documented, the same is true of sleeping aids such as the prescription drug Ambien, which many players privately claim are popular among NHLers.
Generally speaking, there’s a ready supply of whatever a player needs to dull the pain or find sleep – all it takes is a teammate with an extra tablet or two in his shaving kit.
“It still goes on and it always will, guys pass pills around,” said a recently retired NHLer who played the bulk of his career in the Western Conference, where travel schedules are the most punishing.
And despite all the good will and best intentions of the league and the players’ union – and there is plenty of evidence of both from both – the central problem is intractable.
Because of the complexities of schedule-making and the financial situation of teams and the multipurpose buildings they play in, the simplest solution for improving the players’ lot – spreading out the games or playing fewer of them – isn’t practical.
So the specific demands in the eventual contract negotiations will likely have to do with details such as minimizing the number of back-to-back games.
But some players are beginning to advocate for more sweeping change.
Though the NHLPA has yet to pick its bargaining committee for the contract negotiations – an announcement is said to be imminent – there is talk it may seek to address some of the nuts and bolts regarding the league schedule and associated logistical issues at the negotiating table.
The other main barrier is a cultural one – professional hockey does all sorts of things that make little or no sense from a high-performance training standpoint.
Reams of studies have concluded it’s best for athletes to train around the same time they compete and that rest is as important as effort.
And yet hockey teams, which invariably play in the evening, universally practise in the morning. Game-day skates, pioneered in the NHL by former Chicago Blackhawks coach Rudy Pilous to keep his players from carousing too late, are another tradition that runs counter to the science.
“Their main usefulness is as mental preparation, routine, there’s no discernible physical benefit. In my view they should only ever be optional, to have everyone skate is an aberration. Everyone recovers differently, everyone needs different levels of rest,” said Georges Larivière, an emeritus professor of kinesiology at the Université de Montreal who has long studied hockey players. “And everyone knows that no practice is truly optional if you’re a rookie or a fourth-line player.”
For all that, many players are comfortable with the ritual – beyond the patchwork of practices among NHL teams, there is a range of opinion expressed by those in uniform.
“I think you at least have to give guys the option, I know I like to feel the ice and get my legs going,” said 23-year-old Montreal Canadiens defenceman P.K. Subban.
Among other players, the complaints are legion: coaches who insist players be at the rink for team meetings barely six hours after their charter has flown in; practice ice that is dangerously rutted and chippy because of the number of concerts and other events held in a typical NHL arena.
Larivière said teams typically don’t pay as much attention as they should to rest and recovery or to individual training and that the NHL routine becomes “a vicious circle.”
Other professional sports leagues, such as the NFL, have clauses in their collective agreements that limit the amount of time players can spend at the team facility and stipulate things such as the length of practices.
The NHL has no such strictures. The closest thing is Article 16.6 of the CBA, which reads: “practice sessions shall be scheduled at reasonable times in accordance with the general practice of clubs in the league.”
Some players see that as an area for improvement.
“The more guys are tired, the more likely they are to get hurt. This is going to be an issue [in the negotiations], maybe not the biggest issue, but it’s something a lot of guys are talking about,” said a player representative from an Eastern Conference team. Though the NHLPA has yet to set its negotiating positions, an official with the union said the player’s characterization “is accurate as far as we’re concerned.”
It’s not as though teams are completely insensitive to the concerns.
Many coaches only hold optional game-day skates and limit full-fledged practices to once or twice a week – and league-wide there is unprecedented emphasis on nutrition, preventive therapy and hockey-specific fitness training.
More and more teams are altering their travel policies and plumping for an extra night’s stay in a hotel after road games in faraway cities.
Several teams on the cutting edge, the Canucks and Calgary Flames chief among them, have done things such as consulting sleep doctors and arranging their practice and travel schedules in such a way as to minimize the physical demands on players.
“The games are so close, rest becomes a big factor,” Burrows said. “They’ve given us tricks to control our breathing, methods to help us sleep, whether it’s iPhone apps or other things to lower your heart rate and allow you to get better sleep. It works.”
But evidently not for everyone.

Wednesday, May 2, 2012

Theralase Announces Year End Financials


Theralase Holds Revenues Stable While Advancing Therapeutic Laser, Cancer and Bacteria Destruction Technologies

Toronto, Ontario – April 30, 2012, Theralase Technologies Inc. (TSXV: TLT) announced its year end 2011 financial results today.

Total revenue for the twelve months ended December 31, 2011 remained stable at $2,027,058 compared to $2,040,537 for the same period in 2010.

Selling expenses increased by 55%, to $1,060,288 for the twelve month period ended December 31, 2011 compared to $681,968 for the same period in 2010. The percentage increase was due to increased spending on salaries, marketing, advertising and travel related expenses, as a result of the Company’s expansion efforts into the US medical market. 

Administrative expenses decreased from $1,241,126 for the twelve months ended December 31, 2010 to $1,028,431 for the same period in 2011 representing a decrease of 17%. The decrease in administrative expenditures is primarily due to reductions in the costs associated with stock based compensation.

Research and development costs increased to $867,872 for the year ended December 31, 2011 compared to $688,411 for the previous year. This represents a 26% increase in expenditures, which is due to the costs required to commercialize the TLC-2000 biofeedback laser and research and development of the TLC-3000 Photo Dynamic Compound cancer and bacteria destruction technology.

The net loss for the year ended December 31, 2011 was $1,453,974 which included $74,922 of net non-cash expenses (amortization, stock-based compensation expense, foreign exchange gain/loss and lease inducements) compared to a net loss in 2010 of $1,168,350, which included $271,086 of net non-cash expenses.  The increase in net loss is due to capital investments in three fundamental areas: sales and marketing expansion of the therapeutic laser technology into the US medical market, commercialization of the patented TLC-2000 Biofeedback Therapeutic Laser due for launch in 4Q2012 and research and development of the TLC-3000 Photo Dynamic Compound cancer and bacteria destruction technology due for completion of the pre-clinical phase by 4Q2012..

Roger Dumoulin-White, President and CEO of Theralase Technologies Inc. stated, “The Company is preparing for the unveiling of its next generation patented TLC-2000 Biofeedback Therapeutic Laser in 4Q2012, while on the research front, exciting progress is being made in the destruction of cancer cells and bacteria utilizing Theralase’s patented Photo Dynamic Compounds (PDCs). In order to capitalize on this research and unlock shareholder value, we are presently investigating strategic partnerships focused on the early commercialization of both of these ground breaking technologies.”

Subsequent to the Company’s year-end, Theralase completed a private placement on April 13, 2012 for gross proceeds of $750,000.

About Theralase Technologies Inc.

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing. As well, these applications extend to the care of animals by veterinarians. Theralase is currently developing patented Photo Dynamic Compounds (PDCs) that are able to target and destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technology.

The complete consolidated financial statements and MD&A for twelve months ending December 31, 2011 may be viewed at www.theralase.com  and www.sedar.com .

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin - White,                                                                         
President & CEO                                                                                       
416-447-8455 ext. 225                                                                              

Kristina Hachey
Chief Financial Officer
416-447-8455 ext. 224
khachey@theralase.com                                                                         

Greg Bewsh
Director of Investor Relations
416-447-8455 ext. 262

Arkady Mandel
Chief Scientific Officer
416-447-8455 ext. 242

Why Invest in Theralase?


  • Proven clinical technology (TLC-1000)
  • Commercial therapeutic laser business and brand developed over last 17 years
  • No debt
  • Positive cash flow / double digit growth
  • PDC cancer destruction in animals helps pay for human trials
  • Competitive technical advantage (Cellular pathways: iNOS, ATP, Na+ / K+)
  • Large addressable US market ($ billions)
  • Future technology (Patented biofeedback technology and patented PDC cancer destruction)
  • Opportunity for growth (revenue, profit)
  • IP protection (multiple issued patents)
  • Experienced management team (20+ years)
  • Clear vision and execution strategy
For more information please contact Greg Bewsh at 1-866-843-5273 or visit www.theralase.com